Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.
byBenzinga Newsdesk
September 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Investor Fear Eases After Nasdaq Rises More Than 2%

By Lisa Levin
December 30, 4:08 AM
The CNN Money Fear and Greed index showed some easing in the fear level among US investors after US stocks closed higher on Thursday. US stocks recorded gains after data from the Labor Department showed a rise in jobless claims from last week. US initial jobless claims increased by 9,000 to 225,000 in the week ending December 24, compared to market expectations of 225,000.

AAPL